Raptor glides on promising phase II/III data in Huntington’s
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) hit a 52-week high of $17.69 Thursday after the company reported encouraging top-line results from a planned 18-month analysis of an ongoing, three-year phase II/III trial of RP103 (delayed-release cysteamine) in Huntington’s disease (HD).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST